JEJames J. Egan

James J. Egan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James J. Egan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Nizar Yonan

    2 shared publications
  • She S. Lok

    North West Lung Centre, Wythenshawe Hospital, Manchester, United Kingdom

    2 shared publications
  • Abdul K. Deiraniya

    North West Lung Centre and Department of Cardiothoracic Surgery, Wythenshawe Hospital, and Public Health Laboratory, Withington Hospital, Manchester, England

    1 shared publication
  • Andrew Fox

    North West Lung Centre and Department of Cardiothoracic Surgery, Wythenshawe Hospital, and Public Health Laboratory, Withington Hospital, Manchester, England

    1 shared publication
  • Andrew J. Turner

    North West Lung Centre and Department of Cardiothoracic Surgery, Wythenshawe Hospital, and Public Health Laboratory, Withington Hospital, Manchester, England

    1 shared publication
  • Ashley Woodcock

    University of Manchester, Manchester, UK

    1 shared publication

Latest Publications

    • 1 November 1998
      • Vol. 17  (11) , 1039-44

    Pharmacologic therapy of idiopathic pulmonary fibrosis.

    by J Egan

  • Idiopathic Pulmonary Fibrosis and Cyclosporine

    by She S. Lok, Elaine Smith, Helen M. Doran, Richard Sawyer, Nizar Yonan, James J. Egan


  • PREEMPTIVE TREATMENT FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE

    by Jim J. Egan, Joyce Lomax, Lisa Barber, She S. Lok, Ruth Martyszczuk, Nizar Yonan, Andrew Fox, Abdul K. Deiraniya, Andrew J. Turner, Ashley A. Woodcock

    Background. Rapid quantifiable diagnostic techniques for the diagnosis of cytomegalovirus (CMV) infection may predict patients at risk of CMV pneumonitis and allow preemptive antiviral treatment. Methods. Using CMV antigenemia as a prospective surveillance technique for CMV infection, we compared the outcome of preemptive treatment (PT) with ganciclovir, 10 mg/kg/day for 21 days directed by “high levels” of CMV antigenemia (PT group, n=19), with the outcome in a group of historical controls (n=18) treated with ganciclovir when CMV illness occurred. Greater than 50 antigen-positive cells per 2×105 polymorphonuclear leukocytes was considered to be high-level antigenemia. Results. Nine of the 18 controls developed high-level CMV antigenemia at a median of 33 days (range: 13-65 days) and 5 of the 9 developed CMV disease. Ten of the 19 PT group had high levels of CMV antigenemia detected at a median of 47 days (range: 20-63 days) and were given ganciclovir; none developed CMV disease. There was a significantly lower incidence of CMV disease in the PT group in comparison to controls (0 of 19 vs. 5 of 18:P=0.019). Conclusion. We have reduced the incidence of CMV disease using preemptive treatment, and because of a 100% negative predictive value, we omitted unnecessary antiviral prophylaxis for many at-risk patients.